8-K/A: Rafael Holdings Revises Subscription Rights for $25 Million Rights Offering

Rafael Holdings announces revised subscription rights for its previously announced $25 million rights offering to support the development of Trappsol Cyclo.

Summary

• Rafael Holdings, Inc. announced revised subscription rights for its previously announced rights offering.
• The rights offering aims to raise $25 million to support the development and potential launch of Trappsol Cyclo.
• Holders of record as of May 9, 2025, are eligible to participate, with a purchase deadline of May 8, 2025, to be considered a holder of record.
• Each subscription right now entitles the holder to purchase 0.603 of a share of Class B Common Stock at $1.28 per share, a change from the previously announced 0.526 of a share.
• Subscription rights can only be exercised in whole numbers, with fractional shares not being issued.
• Howard Jonas, the Executive Chairman, will purchase any unsubscribed shares through a Standby Purchase Agreement.
• The subscription period runs from May 13, 2025, to May 29, 2025, unless extended or terminated.
• D.F. King & Co., Inc. is the Information Agent for the rights offering.

Sentiment

Score: 7

Explanation: The announcement is generally positive as it secures funding for a key drug development program. The revision of subscription rights is a neutral event, and the standby purchase agreement provides confidence in the offering's success. However, the inherent risks associated with drug development temper the overall sentiment.

Positives

• The rights offering aims to raise $25 million to support the development of Trappsol Cyclo.
• Howard Jonas's Standby Purchase Agreement provides assurance that the offering will be fully subscribed.
• The funds raised will support the development of Trappsol Cyclo, a potential treatment for Niemann-Pick Disease Type C1 (NPC1).

Negatives

• The subscription rights are non-transferable.
• Fractional shares will not be issued, and the number of shares purchasable will be rounded down.
• The rights offering is subject to certain conditions and may be terminated by Rafael Holdings.

Risks

• The rights offering is subject to certain conditions and may be terminated by Rafael Holdings prior to its expiration date.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The success of Trappsol Cyclo is not guaranteed and is subject to clinical trial outcomes and regulatory approvals.

Future Outlook

The company intends to use the proceeds from the rights offering to support the development and potential launch of Trappsol Cyclo.

Management Comments

• Rafael Holdings has not made any recommendation regarding whether Holders should exercise their subscription rights.
• Holders are encouraged to carefully review the subscription materials and consult with their legal and financial advisors.

Industry Context

Rights offerings are a common method for companies, particularly in the biotechnology sector, to raise capital for research and development. The funds are earmarked for the development of Trappsol Cyclo, a drug targeting a rare disease, which aligns with the industry's focus on orphan drug development.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as BioMarin Pharmaceutical and Vertex Pharmaceuticals, often utilize similar financing strategies to fund their drug development pipelines.
• The $25 million rights offering is relatively small compared to some larger capital raises in the industry, but it is appropriately sized for a company of Rafael Holdings' scale and the specific needs of the Trappsol Cyclo program.
• The standby purchase agreement with Howard Jonas is a common mechanism to ensure the success of rights offerings, similar to arrangements seen in other biotech capital raises.

Stakeholder Impact

• Shareholders have the opportunity to participate in the rights offering and potentially increase their stake in the company.
• The successful completion of the rights offering will provide Rafael Holdings with the necessary capital to advance the development of Trappsol Cyclo, potentially benefiting patients with Niemann-Pick Disease Type C1 (NPC1).

Next Steps

• Holders of record as of May 9, 2025, should review the subscription materials.
• Holders should consult with their legal and financial advisors before making a decision.
• The subscription period runs from May 13, 2025, to May 29, 2025.

Key Dates

Keywords

rights offering, subscription rights, Trappsol Cyclo, Rafael Holdings, Class B Common Stock, Howard Jonas, Niemann-Pick Disease Type C1, NPC1, pharmaceutical, biotechnology